Cortechs.ai | NeuroQuant<sup>®</sup>: Contrast agents not required

NeuroQuant®: Contrast agents not required

Factors which degrade the technical quality of MR images or pathologic processes, which significantly affect neuroanatomic structure, may decrease the accuracy of NeuroQuant® output. One of these factors is the use of contrast agents.

Contrast agents are typically used to study vasculature, something that is not needed for volumetric MR imaging. NeuroQuant requires a non-contrasted, 3D T1 sagittal sequence to segment and measure brain structure volumes.

NeuroQuant does not support a contrast enhanced study. The presence of contrast will cause misregistration of cortical and subcortical structures. The segmentation, volumetrics and normative comparisons will be inaccurate when contrast agents are used.

Some examples of NeuroQuant processed with and without contrast agents are shown below.

Cortechs.ai | NeuroQuant<sup>®</sup>: Contrast agents not required

More information about using NeuroQuant can be found here.

More Resources

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.
Scroll to Top